| PRODUCT | DETAILS |
|---|---|
| Camrelizumab | — |
| Famitinib | — |
| SHR-1701 | — |
| HRS9531 | — |
China's largest domestic innovative pharmaceutical company by R&D spend (~$1.5B USD annually, ~25% of revenue). Over 50 drugs in clinical development. Camrelizumab (PD-1 inhibitor) is its flagship. Aggressively out-licensing to western partners including deals with Merck and Elevar Therapeutics. Shanghai A-share listed only.